BT032: A Novel NLRP1 & NLRP3 Inhibitor to Treat Pulmonary Inflammation

Time: 11:30 am
day: Day 1 - Track B - Morning

Details:

  • BT032 is a novel first in class NLRP1 and NLRP3 inhibitor
  • BT032 directly targets NLRP1 and NLRP3 activity
  • BT032 reduces IAV-induced pulmonary inflammation in vivo

Speakers: